|
1
|
Wiechno P, Kucharz J, Sadowska M,
Michalski W, Sikora-Kupis B, Jonska-Gmyrek J, Poniatowska G,
Nietupski K, Ossolinski K and Demkow T: Contemporary treatment of
metastatic renal cell carcinoma. Med Oncol. 35:1562018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hammers HJ, Plimack ER, Infante JR, Rini
BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA,
et al: Safety and efficacy of nivolumab in combination with
ipilimumab in metastatic renal cell carcinoma: The CheckMate 016
study. J Clin Oncol. 35:3851–3858. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galdiero MR, Marone G and Mantovani A:
Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol.
10:a0285302018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kay J, Thadhani E, Samson L and Engelward
B: Inflammation-induced DNA damage, mutations and cancer. DNA
Repair (Amst). 83:1026732019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Korniluk A, Koper O, Kemona H and
Dymicka-Piekarska V: From inflammation to cancer. Ir J Med Sci.
186:57–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ha H, Debnath B and Neamati N: Role of the
CXCL8-CXCR1/2 axis in cancer and inflammatory diseases.
Theranostics. 7:1543–1588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brighi N, Farolfi A, Conteduca V, Gurioli
G, Gargiulo S, Gallà V, Schepisi G, Lolli C, Casadei C and De
Giorgi U: The interplay between inflammation, anti-angiogenic
agents, and immune checkpoint inhibitors: Perspectives for renal
cell cancer treatment. Cancers (Basel). 11:19352019. View Article : Google Scholar
|
|
10
|
Nakamura K and Smyth MJ: Targeting
cancer-related inflammation in the era of immunotherapy. Immunol
Cell Biol. 95:325–332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ngabire D and Kim GD: Autophagy and
inflammatory response in the tumor microenvironment. Int J Mol Sci.
18:20162017. View Article : Google Scholar
|
|
13
|
Todoric J, Antonucci L and Karin M:
Targeting inflammation in cancer prevention and therapy. Cancer
Prev Res (Phila). 9:895–905. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Borroni EM, Savino B, Bonecchi R and
Locati M: Chemokines sound the alarmin: The role of atypical
chemokine in inflammation and cancer. Semin Immunol. 38:63–71.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marelli G, Sica A, Vannucci L and Allavena
P: Inflammation as target in cancer therapy. Curr Opin Pharmacol.
35:57–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Munn LL: Cancer and inflammation. Wiley
Interdiscip Rev Syst Biol Med. 9:2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Murata M: Inflammation and cancer. Environ
Health Prev Med. 23:502018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Urban-Wojciuk Z, Khan MM, Oyler BL,
Fåhraeus R, Marek-Trzonkowska N, Nita-Lazar A, Hupp TR and Goodlett
DR: The role of TLRs in anti-cancer immunity and tumor rejection.
Front Immunol. 10:23882019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kunnumakkara AB, Sailo BL, Banik K, Harsha
C, Prasad S, Gupta SC, Bharti AC and Aggarwal BB: Chronic diseases,
inflammation, and spices: How are they linked? J Transl Med.
16:142018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kundu JK and Surh YJ: Emerging avenues
linking inflammation and cancer. Free Radic Biol Med. 52:2013–2037.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taniguchi K and Karin M: NF-κB,
inflammation, immunity and cancer: Coming of age. Nat Rev Immunol.
18:309–324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu YS, Han X and Liu XH: STAT3: A
potential drug target for tumor and inflammation. Curr Top Med
Chem. 19:1305–1317. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martínez-Sáez O, Gajate Borau P,
Alonso-Gordoa T, Molina-Cerrillo J and Grande E: Targeting HIF-2 α
in clear cell renal cell carcinoma: A promising therapeutic
strategy. Crit Rev Oncol Hematol. 111:117–123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tarade D and Ohh M: The HIF and other
quandaries in VHL disease. Oncogene. 37:139–147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chappell JC, Payne LB and Rathmell WK:
Hypoxia, angiogenesis, and metabolism in the hereditary kidney
cancers. J Clin Invest. 129:442–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duan C: Hypoxia-inducible factor 3
biology: Complexities and emerging themes. Am J Physiol Cell
Physiol. 310:C260–C269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choudhry H and Harris AL: Advances in
hypoxia-inducible factor biology. Cell Metab. 27:281–298. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Strowitzki MJ, Cummins EP and Taylor CT:
Protein hydroxylation by hypoxia-inducible factor (HIF)
hydroxylases: Unique or Ubiquitous? Cells. 8:3842019. View Article : Google Scholar
|
|
32
|
Yu Y, Yu Q and Zhang X: Allosteric
inhibition of HIF-2α as a novel therapy for clear cell renal cell
carcinoma. Drug Discov Today. 24:2332–2340. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schödel J, Grampp S, Maher ER, Moch H,
Ratcliffe PJ, Russo P and Mole DR: Hypoxia, hypoxia-inducible
transcription factors, and renal cancer. Eur Urol. 69:646–657.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qureshi AS and Ali S: Review: Warburg
effect and renal cancer caused by errs in fumarate hydratase
encoding gene. Pak J Pharm Sci. 32:743–749. 2019.PubMed/NCBI
|
|
35
|
Bao Y, Wang Z, Liu B, Lu X, Xiong Y, Shi
J, Li P, Chen J, Zhang Z, Chen M, et al: A feed-forward loop
between nuclear translocation of CXCR4 and HIF-1α promotes renal
cell carcinoma metastasis. Oncogene. 38:881–895. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mossmann D, Park S and Hall MN: mTOR
signalling and cellular metabolism are mutual determinants in
cancer. Nat Rev Cancer. 18:744–757. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hua H, Kong Q, Zhang H, Wang J, Luo T and
Jiang Y: Targeting mTOR for cancer therapy. J Hematol Oncol.
12:712019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Murugan AK: mTOR: Role in cancer,
metastasis and drug resistance. Semin Cancer Biol. 59:92–111. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saxton RA and Sabatini DM: mTOR signaling
in growth, metabolism, and disease. Cell. 168:960–976. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim LC, Cook RS and Chen J: mTORC1 and
mTORC2 in cancer and the tumor microenvironment. Oncogene.
36:2191–2201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song M, Bode AM, Dong Z and Lee MH: AKT as
a therapeutic target for cancer. Cancer Res. 79:1019–1031. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lieberthal W and Levine JS: The role of
the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc
Nephrol. 20:2493–2502. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Deng W, Han W, Fan T, Wang X, Cheng Z, Wan
B and Chen J: Scutellarin inhibits human renal cancer cell
proliferation and migration via upregulation of PTEN. Biomed
Pharmacother. 107:1505–1513. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Figlin RA, Kaufmann I and Brechbiel J:
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New
strategies for overcoming resistance to VEGFR and mTORC1
inhibitors. Int J Cancer. 133:788–796. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ben-Sahra I and Manning BD: mTORC1
signaling and the metabolic control of cell growth. Curr Opin Cell
Biol. 45:72–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Duran I, Lambea J, Maroto P,
González-Larriba JL, Flores L, Granados-Principal S, Graupera M,
Sáez B, Vivancos A and Casanovas O: Resistance to targeted
therapies in renal cancer: The importance of changing the mechanism
of action. Target Oncol. 12:19–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Poletto V, Rosti V, Biggiogera M, Guerra
G, Moccia F and Porta C: The role of endothelial colony forming
cells in kidney cancer's pathogenesis, and in resistance to
anti-VEGFR agents and mTOR inhibitors: A speculative review. Crit
Rev Oncol Hematol. 132:89–99. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ma WW and Jimeno A: Temsirolimus. Drugs
Today (Barc). 43:659–669. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bedke J, Stühler V, Stenzl A and Brehmer
B: Immunotherapy for kidney cancer: Status quo and the future. Curr
Opin Urol. 28:8–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wajant H and Beilhack A: Targeting
regulatory T cells by addressing tumor necrosis factor and its
receptors in allogeneic hematopoietic cell transplantation and
cancer. Front Immunol. 10:20402019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Martínez-Reza I, Díaz L and García-Becerra
R: Preclinical and clinical aspects of TNF-α and its receptors
TNFR1 and TNFR2 in breast cancer. J Biomed Sci. 24:902017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ting AT and Bertrand MJM: More to life
than NF-κB in TNFR1 signaling. Trends Immunol. 37:535–545. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mehta AK, Gracias DT and Croft M: TNF
activity and T cells. Cytokine. 101:14–18. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang J and Al-Lamki RS: Tumor necrosis
factor receptor 2: Its contribution to acute cellular rejection and
clear cell renal carcinoma. Biomed Res Int. 2013:8213102013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qi H and Ohh M: The von Hippel-Lindau
tumor suppressor protein sensitizes renal cell carcinoma cells to
tumor necrosis factor-induced cytotoxicity by suppressing the
nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res.
63:7076–7080. 2003.PubMed/NCBI
|
|
56
|
Al-Lamki RS, Sadler TJ, Wang J, Reid MJ,
Warren AY, Movassagh M, Lu W, Mills IG, Neal DE, Burge J, et al:
Tumor necrosis factor receptor expression and signaling in renal
cell carcinoma. Am J Pathol. 177:943–954. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Borghi A, Verstrepen L and Beyaert R:
TRAF2 multitasking in TNF receptor-induced signaling to NF-κB, MAP
kinases and cell death. Biochem Pharmacol. 116:1–10. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhao X, Rong L, Zhao X, Li X, Liu X, Deng
J, Wu H, Xu X, Erben U, Wu P, et al: TNF signaling drives
myeloid-derived suppressor cell accumulation. J Clin Invest.
122:4094–4104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sheng Y, Li F and Qin Z: TNF receptor 2
makes tumor necrosis factor a friend of tumors. Front Immunol.
9:11702018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang S, Yang X, Wang L and Zhang C:
Interplay between inflammatory tumor microenvironment and cancer
stem cells. Oncol Lett. 16:679–686. 2018.PubMed/NCBI
|
|
61
|
Trivedi S and Starz-Gaiano M: Drosophila
Jak/STAT signaling: Regulation and relevance in human cancer and
metastasis. Int J Mol Sci. 19:40562018. View Article : Google Scholar
|
|
62
|
Chen Y, Zhu Y, Sheng Y, Xiao J, Xiao Y,
Cheng N, Chai Y, Wu X, Zhang S and Xiang T: SIRT1 downregulated FGB
expression to inhibit RCC tumorigenesis by destabilizing STAT3. Exp
Cell Res. 382:1114662019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu Y, Wang JX, Nie ZY, Wen Y, Jia XJ,
Zhang LN, Duan HJ and Shi YH: Upregulation of ERp57 promotes clear
cell renal cell carcinoma progression by initiating a STAT3/ILF3
feedback loop. J Exp Clin Cancer Res. 38:4392019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wei X, Yu L and Li Y: PBX1 promotes the
cell proliferation via JAK2/STAT3 signaling in clear cell renal
carcinoma. Biochem Biophys Res Commun. 500:650–657. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Huynh J, Etemadi N, Hollande F, Ernst M
and Buchert M: The JAK/STAT3 axis: A comprehensive drug target for
solid malignancies. Semin Cancer Biol. 45:13–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Fathi N, Rashidi G, Khodadadi A, Shahi S
and Sharifi S: STAT3 and apoptosis challenges in cancer. Int J Biol
Macromol. 117:993–1001. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Guanizo AC, Fernando CD, Garama DJ and
Gough DJ: STAT3: A multifaceted oncoprotein. Growth Factors.
36:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Galoczova M, Coates P and Vojtesek B:
STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett.
23:122018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Huynh J, Chand A, Gough D and Ernst M:
Therapeutically exploiting STAT3 activity in cancer - using tissue
repair as a road map. Nat Rev Cancer. 19:82–96. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yeung YT, Aziz F, Guerrero-Castilla A and
Arguelles S: Signaling pathways in inflammation and
anti-inflammatory therapies. Curr Pharm Des. 24:1449–1484. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wang Y, Fu D, Chen Y, Su J, Wang Y, Li X,
Zhai W, Niu Y, Yue D and Geng H: G3BP1 promotes tumor progression
and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal
cell carcinomas. Cell Death Dis. 9:5012018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Taher MY, Davies DM and Maher J: The role
of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc
Trans. 46:1449–1462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kampan NC, Xiang SD, McNally OM, Stephens
AN, Quinn MA and Plebanski M: Immunotherapeutic interleukin-6 or
interleukin-6 receptor blockade in cancer: Challenges and
opportunities. Curr Med Chem. 25:4785–4806. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ray K, Ujvari B, Ramana V and Donald J:
Cross-talk between EGFR and IL-6 drives oncogenic signaling and
offers therapeutic opportunities in cancer. Cytokine Growth Factor
Rev. 41:18–27. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Jordan SC, Choi J, Kim I, Wu G, Toyoda M,
Shin B and Vo A: Interleukin-6, a cytokine critical to mediation of
inflammation, autoimmunity and allograft rejection: Therapeutic
implications of IL-6 receptor blockade. Transplantation. 101:32–44.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Jones SA and Jenkins BJ: Recent insights
into targeting the IL-6 cytokine family in inflammatory diseases
and cancer. Nat Rev Immunol. 18:773–789. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kamińska K, Czarnecka AM, Escudier B, Lian
F and Szczylik C: Interleukin-6 as an emerging regulator of renal
cell cancer. Urol Oncol. 33:476–485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Qi QR and Yang ZM: Regulation and function
of signal transducer and activator of transcription 3. World J Biol
Chem. 5:231–239. 2014.PubMed/NCBI
|
|
80
|
Jones SA, Horiuchi S, Topley N, Yamamoto N
and Fuller GM: The soluble interleukin 6 receptor: Mechanisms of
production and implications in disease. FASEB J. 15:43–58. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Matsumoto S, Hara T, Mitsuyama K, Yamamoto
M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S and Takada T:
Essential roles of IL-6 trans-signaling in colonic epithelial
cells, induced by the IL-6/soluble-IL-6 receptor derived from
lamina propria macrophages, on the development of
colitis-associated premalignant cancer in a murine model. J
Immunol. 184:1543–1551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Oguro T, Ishibashi K, Sugino T, Hashimoto
K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T,
et al: Humanised antihuman IL-6R antibody with interferon inhibits
renal cell carcinoma cell growth in vitro and in vivo through
suppressed SOCS3 expression. Eur J Cancer. 49:1715–1724. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ueno S, Saito S, Wada T, Yamaguchi K,
Satoh M, Arai Y and Miyagi T: Plasma membrane-associated sialidase
is up-regulated in renal cell carcinoma and promotes
interleukin-6-induced apoptosis suppression and cell motility. J
Biol Chem. 281:7756–7764. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Annibaldi A and Meier P: Checkpoints in
TNF-induced cell death: Implications in inflammation and cancer.
Trends Mol Med. 24:49–65. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Patel HJ and Patel BM: TNF-α and cancer
cachexia: Molecular insights and clinical implications. Life Sci.
170:56–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Josephs SF, Ichim TE, Prince SM, Kesari S,
Marincola FM, Escobedo AR and Jafri A: Unleashing endogenous
TNF-alpha as a cancer immunotherapeutic. J Transl Med. 16:2422018.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Harrison ML, Obermueller E, Maisey NR,
Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, et
al: Tumor necrosis factor alpha as a new target for renal cell
carcinoma: Two sequential phase II trials of infliximab at standard
and high dose. J Clin Oncol. 25:4542–4549. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Dosquet C, Coudert MC, Lepage E, Cabane J
and Richard F: Are angiogenic factors, cytokines, and soluble
adhesion molecules prognostic factors in patients with renal cell
carcinoma? Clin Cancer Res. 3:2451–2458. 1997.PubMed/NCBI
|
|
89
|
Wong SHM, Kong WY, Fang CM, Loh HS, Chuah
LH, Abdullah S and Ngai SC: The TRAIL to cancer therapy: Hindrances
and potential solutions. Crit Rev Oncol Hematol. 143:81–94. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
von Karstedt S, Montinaro A and Walczak H:
Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer. 17:352–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yuan X, Gajan A, Chu Q, Xiong H, Wu K and
Wu GS: Developing TRAIL/TRAIL death receptor-based cancer
therapies. Cancer Metastasis Rev. 37:733–748. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Xu YM, Brooks AD, Wijeratne EM, Henrich
CJ, Tewary P, Sayers TJ and Gunatilaka AA: 17β-Hydroxywithanolides
as sensitizers of renal carcinoma cells to tumor necrosis factor-α
related apoptosis inducing ligand (TRAIL) mediated apoptosis:
Structure-activity relationships. J Med Chem. 60:3039–3051. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Cannarile MA, Weisser M, Jacob W, Jegg AM,
Ries CH and Rüttinger D: Colony-stimulating factor 1 receptor
(CSF1R) inhibitors in cancer therapy. J Immunother Cancer.
5:532017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Menke J, Kriegsmann J, Schimanski CC,
Schwartz MM, Schwarting A and Kelley VR: Autocrine CSF-1 and CSF-1
receptor coexpression promotes renal cell carcinoma growth. Cancer
Res. 72:187–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ngambenjawong C, Gustafson HH and Pun SH:
Progress in tumor-associated macrophage (TAM)-targeted
therapeutics. Adv Drug Deliv Rev. 114:206–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Cassetta L, Fragkogianni S, Sims AH,
Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P,
Lin EY, et al: Human tumor-associated macrophage and monocyte
transcriptional landscapes reveal cancer-specific reprogramming,
biomarkers, and therapeutic targets. Cancer Cell. 35:588–602.e10.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Achkova D and Maher J: Role of the
colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer.
Biochem Soc Trans. 44:333–341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Peyraud F, Cousin S and Italiano A: CSF-1R
inhibitor development: Current clinical status. Curr Oncol Rep.
19:702017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Li X, Qin Z, Xue J, Zhang J, Zheng Y, Xu
W, Xu T and Zou Q: Genetic variants in macrophage
colony-stimulating factor are associated with risk of renal cell
carcinoma in a Chinese population. Int J Biol Markers. 33:321–328.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Nagarsheth N, Wicha MS and Zou W:
Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat Rev Immunol. 17:559–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Cimadamore A, Scarpelli M, Piva F, Massari
F, Gasparrini S, Doria A, Cheng L, Lopez-Beltran A and Montironi R:
Activity of chemokines in prostate and renal tumors and their
potential role as future therapeutic targets. Future Oncol.
13:1105–1114. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhou W, Guo S, Liu M, Burow ME and Wang G:
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Curr Med Chem.
26:3026–3041. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Si X, Ma J, Yu F, Zhao H, Huang H and Sun
YW: Clinicopathological and prognostic significance of CXCR4 high
expression in renal cell carcinoma: A meta-analysis and literature
review. Int J Surg. 71:12–18. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Micucci C, Matacchione G, Valli D, Orciari
S and Catalano A: HIF2α is involved in the expansion of
CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J
Cancer. 113:1178–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Elhence P: A Commentary on
‘Clinico-pathological and prognostic significance of CXCR4 high
expression in renal cell carcinoma: A meta-analysis and literature
review’. (Int J Surg 2019; 71: 12–18). Int J Surg. 72:214–215.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ieranò C, Santagata S, Napolitano M,
Guardia F, Grimaldi A, Antignani E, Botti G, Consales C, Riccio A,
Nanayakkara M, et al: CXCR4 and CXCR7 transduce through mTOR in
human renal cancer cells. Cell Death Dis. 5:e13102014. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Adlere I, Caspar B, Arimont M, Dekkers S,
Visser K, Stuijt J, de Graaf C, Stocks M, Kellam B, Briddon S, et
al: Modulators of CXCR4 and CXCR7/ACKR3 function. Mol Pharmacol.
96:737–752. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Salazar N and Zabel BA: Support of tumor
endothelial cells by chemokine receptors. Front Immunol.
10:1472019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Morein D, Erlichman N and Ben-Baruch A:
Beyond cell motility: The expanding roles of chemokines and their
receptors in malignancy. Front Immunol. 11:9522020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Nazari A, Khorramdelazad H and Hassanshahi
G: Biolog-ical/pathological functions of the CXCL12/CXCR4/CXCR7
axes in the pathogenesis of bladder cancer. Int J Clin Oncol.
22:991–1000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Daniel SK, Seo YD and Pillarisetty VG: The
CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in
gastrointestinal malignancies. Semin Cancer Biol. 65:176–188. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cabrero-de Las Heras S and
Martínez-Balibrea E: CXC family of chemokines as prognostic or
predictive biomarkers and possible drug targets in colorectal
cancer. World J Gastroenterol. 24:4738–4749. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Krikun G: The CXL12/CXCR4/CXCR7 axis in
female reproductive tract disease: Review. Am J Reprod Immunol.
80:e130282018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Cheng X, Wang H, Zhang X, Zhao S, Zhou Z,
Mu X, Zhao C and Teng W: The role of SDF-1/CXCR4/CXCR7 in neuronal
regeneration after cerebral ischemia. Front Neurosci. 11:5902017.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Al-Toub M, Almohawes M, Vishnubalaji R,
Alfayez M, Aldahmash A, Kassem M and Alajez NM: CXCR7 signaling
promotes breast cancer survival in response to mesenchymal stromal
stem cell-derived factors. Cell Death Discov. 5:872019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Floranović MP and Veličković LJ: Effect of
CXCL12 and its receptors on unpredictable renal cell carcinoma.
Clin Genitourin Cancer. 18:e337–e342. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Winer A, Adams S and Mignatti P: Matrix
metalloproteinase inhibitors in cancer therapy: turning past
failures into future successes. Mol Cancer Ther. 17:1147–1155.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Cui N, Hu M and Khalil RA: Biochemical and
biological attributes of matrix metalloproteinases. Prog Mol Biol
Transl Sci. 147:1–73. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Parks WC, Wilson CL and López-Boado YS:
Matrix metalloproteinases as modulators of inflammation and innate
immunity. Nat Rev Immunol. 4:617–629. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Fingleton B: Matrix metalloproteinases as
regulators of inflammatory processes. Biochim Biophys Acta Mol Cell
Res. 1864:2036–2042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Peters F and Becker-Pauly C: Role of
meprin metalloproteases in metastasis and tumor microenvironment.
Cancer Metastasis Rev. 38:347–356. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Su CW, Lin CW, Yang WE and Yang SF: TIMP-3
as a therapeutic target for cancer. Ther Adv Med Oncol. Jul
16–2019.(Epub ahead of print). 1758835919864247, 2019. doi:
10.1177/1758835919864247. View Article : Google Scholar
|
|
123
|
Eckfeld C, Häußler D, Schoeps B, Hermann
CD and Krüger A: Functional disparities within the TIMP family in
cancer: Hints from molecular divergence. Cancer Metastasis Rev.
38:469–481. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Gong D, Zhang J, Chen Y, Xu Y, Ma J, Hu G,
Huang Y, Zheng J, Zhai W and Xue W: The m6A-suppressed
P2RX6 activation promotes renal cancer cells migration and invasion
through ATP-induced Ca(2+) influx modulating ERK1/2 phosphorylation
and MMP9 signaling pathway. J Exp Clin Cancer Res. 38:2332019.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Niu H, Li F, Wang Q, Ye Z, Chen Q and Lin
Y: High expression level of MMP9 is associated with poor prognosis
in patients with clear cell renal carcinoma. PeerJ. 6:e50502018.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Gonzalez-Molina J, Gramolelli S, Liao Z,
Carlson JW, Ojala PM and Lehti K: MMP14 in sarcoma: A regulator of
tumor microenvironment communication in connective tissues. Cells.
8:9912019. View Article : Google Scholar
|
|
127
|
Gifford V and Itoh Y: MT1-MMP-dependent
cell migration: Proteolytic and non-proteolytic mechanisms. Biochem
Soc Trans. 47:811–826. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Cepeda MA, Evered CL, Pelling JJH and
Damjanovski S: Inhibition of MT1-MMP proteolytic function and
ERK1/2 signalling influences cell migration and invasion through
changes in MMP-2 and MMP-9 levels. J Cell Commun Signal.
11:167–179. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Petrella BL and Brinckerhoff CE: Tumor
cell invasion of von Hippel Lindau renal cell carcinoma cells is
mediated by membrane type-1 matrix metalloproteinase. Mol Cancer.
5:662006. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Jiang B, Liu J and Lee MH: Targeting a
designer TIMP-1 to the cell surface for effective MT1-MMP
inhibition: A potential role for the prion protein in renal
carcinoma therapy. Molecules. 24:2552019. View Article : Google Scholar
|
|
131
|
Wu G, Ma Z, Cheng Y, Hu W, Deng C, Jiang
S, Li T, Chen F and Yang Y: Targeting Gas6/TAM in cancer cells and
tumor microenvironment. Mol Cancer. 17:202018. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kovaleva OV, Samoilova DV, Shitova MS and
Gratchev A: Tumor associated macrophages in kidney cancer. Anal
Cell Pathol (Amst). 2016:93075492016.PubMed/NCBI
|
|
133
|
Santoni M, Massari F, Amantini C, Nabissi
M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R,
Tortora G and Cascinu S: Emerging role of tumor-associated
macrophages as therapeutic targets in patients with metastatic
renal cell carcinoma. Cancer Immunol Immunother. 62:1757–1768.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Toge H, Inagaki T, Kojimoto Y, Shinka T
and Hara I: Angiogenesis in renal cell carcinoma: The role of
tumor-associated macrophages. Int J Urol. 16:801–807. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang
J, Zhou Q, Zeng H, Tong S, Wang T, et al: Tumor-associated
macrophage-derived interleukin-23 interlinks kidney cancer
glutamine addiction with immune evasion. Eur Urol. 75:752–763.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Tcyganov E, Mastio J, Chen E and
Gabrilovich DI: Plasticity of myeloid-derived suppressor cells in
cancer. Curr Opin Immunol. 51:76–82. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Sun L, Clavijo PE, Robbins Y, Patel P,
Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, et al:
Inhibiting myeloid-derived suppressor cell trafficking enhances T
cell immunotherapy. JCI Insight. 4:e1268532019. View Article : Google Scholar
|
|
138
|
Zhang J, Shi Z, Xu X, Yu Z and Mi J: The
influence of microenvironment on tumor immunotherapy. FEBS J.
286:4160–4175. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Martinez M and Moon EK: CAR T cells for
solid tumors: New strategies for finding, infiltrating, and
surviving in the tumor microenvironment. Front Immunol. 10:1282019.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Fleming V, Hu X, Weber R, Nagibin V, Groth
C, Altevogt P, Utikal J and Umansky V: targeting myeloid-derived
suppressor cells to bypass tumor-induced immunosuppression. Front
Immunol. 9:3982018. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Hinshaw DC and Shevde LA: The tumor
microenvironment innately modulates cancer progression. Cancer Res.
79:4557–4566. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Marvel D and Gabrilovich DI:
Myeloid-derived suppressor cells in the tumor microenvironment:
Expect the unexpected. J Clin Invest. 125:3356–3364. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Najjar YG, Rayman P, Jia X, Pavicic PG Jr,
Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, et al:
Myeloid-derived suppressor cell subset accumulation in renal cell
carcinoma parenchyma is associated with intratumoral expression of
IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 23:2346–2355. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Kondo T, Nakazawa H, Ito F, Hashimoto Y,
Osaka Y, Futatsuyama K, Toma H and Tanabe K: Favorable prognosis of
renal cell carcinoma with increased expression of chemokines
associated with a Th1-type immune response. Cancer Sci. 97:780–786.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Jöhrer K, Zelle-Rieser C, Perathoner A,
Moser P, Hager M, Ramoner R, Gander H, Höltl L, Bartsch G, Greil R
and Thurnher M: Up-regulation of functional chemokine receptor CCR3
in human renal cell carcinoma. Clin Cancer Res. 11:2459–2465. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Yang JF, Shi SN, Xu WH, Qiu YH, Zheng JZ,
Yu K, Song XY, Li F, Wang Y, Wang R, et al: Screening,
identification and validation of CCND1 and PECAM1/CD31 for
predicting prognosis in renal cell carcinoma patients. Aging
(Albany NY). 11:12057–12079. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Wang C, Wang Y, Hong T, Cheng B, Gan S,
Chen L, Zhang J, Zuo L, Li J and Cui X: Blocking the autocrine
regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the
progression and pazopanib resistance of clear cell renal cell
carcinoma. Cell Death Dis. 11:1172020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119.
2001.PubMed/NCBI
|
|
149
|
Woschek M, Kneip N, Jurida K, Marzi I and
Relja B: Simvastatin reduces cancerogenic potential of renal cancer
cells via geranylgeranyl pyrophosphate and mevalonate pathway. Nutr
Cancer. 68:420–427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Pang X, Si J, Xu S, Li Y and Liu J:
Simvastatin inhibits homocysteine-induced CRP generation via
interfering with the ROS-p38/ERK1/2 signal pathway in rat vascular
smooth muscle cells. Vascul Pharmacol. 88:42–47. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Fang Z, Tang Y, Fang J, Zhou Z, Xing Z,
Guo Z, Guo X, Wang W, Jiao W, Xu Z and Liu Z: Simvastatin inhibits
renal cancer cell growth and metastasis via AKT/mTOR, ERK and
JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Ni X, Hu G and Cai X: The success and the
challenge of all-trans retinoic acid in the treatment of cancer.
Crit Rev Food Sci Nutr. 59 (Sup 1):S71–S80. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Schultze E, Collares T, Lucas CG and
Seixas FK: Synergistic and additive effects of ATRA in combination
with different anti-tumor compounds. Chem Biol Interact. 285:69–75.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Ren M, Pozzi S, Bistulfi G, Somenzi G,
Rossetti S and Sacchi N: Impaired retinoic acid (RA) signal leads
to RARbeta2 epigenetic silencing and RA resistance. Mol Cell Biol.
25:10591–10603. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Chu JH, Gao ZH and Qu XJ: Down-regulation
of sphingosine kinase 2 (SphK2) increases the effects of
all-trans-retinoic acid (ATRA) on colon cancer cells. Biomed
Pharmacother. 68:1089–1097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Zarrabi K and Wu S: An evaluation of
nivolumab for the treatment of metastatic renal cell carcinoma.
Expert Opin Biol Ther. 18:695–705. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Zhang J, Dang F, Ren J and Wei W:
Biochemical aspects of PD-L1 regulation in cancer immunotherapy.
Trends Biochem Sci. 43:1014–1032. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Shi Y: Regulatory mechanisms of PD-L1
expression in cancer cells. Cancer Immunol Immunother.
67:1481–1489. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Ai L, Xu A and Xu J: Roles of PD-1/PD-L1
pathway: Signaling, cancer, and beyond. Adv Exp Med Biol.
1248:33–59. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Chambers CA, Kuhns MS, Egen JG and Allison
JP: CTLA-4-mediated inhibition in regulation of T cell responses:
Mechanisms and manipulation in tumor immunotherapy. Annu Rev
Immunol. 19:565–594. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Izzedine H, Mateus C, Boutros C, Robert C,
Rouvier P, Amoura Z and Mathian A: Renal effects of immune
checkpoint inhibitors. Nephrol Dial Transplant. 32:936–942.
2017.PubMed/NCBI
|
|
163
|
Rotte A: Combination of CTLA-4 and PD-1
blockers for treatment of cancer. J Exp Clin Cancer Res.
38:2552019. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Motzer RJ, Rini BI, McDermott DF, Arén
Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B,
Beuselinck B, Amin A, et al: Nivolumab plus ipilimumab versus
sunitinib in first-line treatment for advanced renal cell
carcinoma: Extended follow-up of efficacy and safety results from a
randomised, controlled, phase 3 trial. Lancet Oncol. 20:1370–1385.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Wculek SK, Cueto FJ, Mujal AM, Melero I,
Krummel MF and Sancho D: Dendritic cells in cancer immunology and
immunotherapy. Nat Rev Immunol. 20:7–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng
P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et
al: Blockade of B7-H1 improves myeloid dendritic cell-mediated
antitumor immunity. Nat Med. 9:562–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Gottfried E, Kunz-Schughart LA, Ebner S,
Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A and Kreutz M:
Tumor-derived lactic acid modulates dendritic cell activation and
antigen expression. Blood. 107:2013–2021. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Delamarre L and Mellman I: Harnessing
dendritic cells for immunotherapy. Semin Immunol. 23:2–11. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Farhood B, Najafi M and Mortezaee K:
CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J
Cell Physiol. 234:8509–8521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Boissonnas A, Fetler L, Zeelenberg IS,
Hugues S and Amigorena S: In vivo imaging of cytotoxic T cell
infiltration and elimination of a solid tumor. J Exp Med.
204:345–356. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Dyck L and Mills KHG: Immune checkpoints
and their inhibition in cancer and infectious diseases. Eur J
Immunol. 47:765–779. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Motz GT and Coukos G: Deciphering and
reversing tumor immune suppression. Immunity. 39:61–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Zitvogel L, Galluzzi L, Smyth MJ and
Kroemer G: Mechanism of action of conventional and targeted
anticancer therapies: Reinstating immunosurveillance. Immunity.
39:74–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Palucka K and Banchereau J:
Dendritic-cell-based therapeutic cancer vaccines. Immunity.
39:38–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Xu W, Atkins MB and McDermott DF:
Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol.
17:137–150. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Chen DS and Hurwitz H: Combinations of
Bevacizumab with cancer immunotherapy. Cancer J. 24:193–204. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Motz GT, Santoro SP, Wang LP, Garrabrant
T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F and Coukos
G: Tumor endothelium FasL establishes a selective immune barrier
promoting tolerance in tumors. Nat Med. 20:607–615. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Kochenderfer JN and Rosenberg SA: Treating
B-cell cancer with T cells expressing anti-CD19 chimeric antigen
receptors. Nat Rev Clin Oncol. 10:267–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Khalil DN, Smith EL, Brentjens RJ and
Wolchok JD: The future of cancer treatment: Immunomodulation, CARs
and combination immunotherapy. Nat Rev Clin Oncol. 13:273–290.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Sourbier C, Lindner V, Lang H, Agouni A,
Schordan E, Danilin S, Rothhut S, Jacqmin D, Helwig JJ and
Massfelder T: The phosphoinositide 3-kinase/Akt pathway: A new
target in human renal cell carcinoma therapy. Cancer Res.
66:5130–5142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Daurkin I, Eruslanov E, Stoffs T, Perrin
GQ, Algood C, Gilbert SM, Rosser CJ, Su LM, Vieweg J and Kusmartsev
S: Tumor-associated macrophages mediate immunosuppression in the
renal cancer microenvironment by activating the 15-lipoxygenase-2
pathway. Cancer Res. 71:6400–6409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Shinko D, Diakos CI, Clarke SJ and Charles
KA: Cancer-related systemic inflammation: The challenges and
therapeutic opportunities for personalized medicine. Clin Pharmacol
Ther. 102:599–610. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Struyf S, Proost P, Vandercappellen J,
Dempe S, Noyens B, Nelissen S, Gouwy M, Locati M, Opdenakker G,
Dinsart C and Van Damme J: Synergistic up-regulation of MCP-2/CCL8
activity is counteracted by chemokine cleavage, limiting its
inflammatory and anti-tumoral effects. Eur J Immunol. 39:843–857.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Iyengar NM, Gucalp A, Dannenberg AJ and
Hudis CA: Obesity and cancer mechanisms: Tumor microenvironment and
inflammation. J Clin Oncol. 34:4270–4276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Voelkel-Johnson C: TRAIL-mediated
signaling in prostate, bladder and renal cancer. Nat Rev Urol.
8:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Chen YS, Hung TW, Su SC, Lin CL, Yang SF,
Lee CC, Yeh CF, Hsieh YH and Tsai JP: MTA2 as a potential biomarker
and its involvement in metastatic progression of human renal cancer
by miR-133b Targeting MMP-9. Cancers (Basel). 11:18512019.
View Article : Google Scholar
|
|
188
|
De Giorgi U, Procopio G, Giannarelli D,
Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli
P, et al: Association of systemic inflammation index and body mass
index with survival in patients with renal cell cancer treated with
nivolumab. Clin Cancer Res. 25:3839–3846. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Qayyum T, McArdle PA, Lamb GW, Going JJ,
Orange C, Seywright M, Horgan PG, Oades G, Aitchison MA and Edwards
J: Prospective study of the role of inflammation in renal cancer.
Urol Int. 88:277–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Wen L, Guo L, Zhang W, Li Y, Jiang W, Di
X, Ma J, Feng L, Zhang K and Shou J: Cooperation between the
inflammation and coagulation systems promotes the survival of
circulating tumor cells in renal cell carcinoma patients. Front
Oncol. 9:5042019. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Sun KH, Sun GH, Wu YC, Ko BJ, Hsu HT and
Wu ST: TNF-α augments CXCR2 and CXCR3 to promote progression of
renal cell carcinoma. J Cell Mol Med. 20:2020–2028. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Barata PC and Rini BI: Treatment of renal
cell carcinoma: Current status and future directions. CA Cancer J
Clin. 67:507–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
